Know Cancer

or
forgot password

Assessment of Liver Cancer Response to Transcatheter Arterial Chemoembolization Using Functional Triple-Phase MultiHance-Enhanced MRI


N/A
18 Years
80 Years
Open (Enrolling)
Both
Hepatocellular Carcinoma

Thank you

Trial Information

Assessment of Liver Cancer Response to Transcatheter Arterial Chemoembolization Using Functional Triple-Phase MultiHance-Enhanced MRI


Inclusion Criteria:



- Outpatients between the ages of 18 - 80 seen in the cardiovascular and interventional
radiology clinic who are scheduled for TACE.

- INR<1.4

- Platelet count > 80,000

Exclusion Criteria:

- Contraindications to TACE procedure

- Unable to have an MRI Scan

- Allergy or hypersensitivity reactions to gadolinium or any other ingredients,
including benzyl alcohol

- Patients with sickle cell anemia , hemoglobinopathies and other hemolytic anemias

- Known clinical hypersensitivity or a history of asthma or allergic respiratory
disorders

- Patients with advanced renal failure (those currently requiring dialysis or with a
Glomerular Filtration Rate<15cc/min)

- Pregnancy

Type of Study:

Interventional

Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

The primary outcome measurement is agreement of tumor necrosis using triple-phase MultiHance-enhanced MRI, with the percent necrosis seen in patients following surgery or tissue biopsy.

Outcome Time Frame:

2007-2010

Safety Issue:

No

Principal Investigator

Ihab Kamel

Investigator Role:

Principal Investigator

Investigator Affiliation:

The Johns Hopkins University

Authority:

United States: Institutional Review Board

Study ID:

J06108

NCT ID:

NCT00539253

Start Date:

September 2007

Completion Date:

December 2012

Related Keywords:

  • Hepatocellular Carcinoma
  • liver cancer
  • transarterial chemoembolization
  • Carcinoma
  • Liver Neoplasms
  • Carcinoma, Hepatocellular

Name

Location

The Johns Hopkins HospitalBaltimore, Maryland  21205